| Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage … A Gallamini, M Hutchings, L Rigacci, L Specht, F Merli, M Hansen, C Patti, ... Journal of clinical oncology 25 (24), 3746-3752, 2007 | 2436* | 2007 |
| Report on the first international workshop on interim-PET scan in lymphoma M Meignan, A Gallamini, M Meignan, A Gallamini, C Haioun Leukemia & lymphoma 50 (8), 1257-1260, 2009 | 828 | 2009 |
| Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma JM Connors, W Jurczak, DJ Straus, SM Ansell, WS Kim, A Gallamini, ... New England Journal of Medicine 378 (4), 331-344, 2018 | 728 | 2018 |
| Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia Italian Cooperative Study Group on Chronic Myeloid Leukemia New England Journal of Medicine 330 (12), 820-825, 1994 | 607 | 1994 |
| Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL) R Bassan, O Spinelli, E Oldani, T Intermesoli, M Tosi, B Peruta, G Rossi, ... Blood, The Journal of the American Society of Hematology 113 (18), 4153-4162, 2009 | 526 | 2009 |
| ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned S Viviani, PL Zinzani, A Rambaldi, E Brusamolino, A Levis, V Bonfante, ... New England Journal of Medicine 365 (3), 203-212, 2011 | 501 | 2011 |
| Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score P Went, C Agostinelli, A Gallamini, PP Piccaluga, S Ascani, E Sabattini, ... Journal of Clinical Oncology 24 (16), 2472-2479, 2006 | 464 | 2006 |
| Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi … A Gallamini, F Zaja, C Patti, A Billio, MR Specchia, A Tucci, A Levis, ... Blood, The Journal of the American Society of Hematology 110 (7), 2316-2323, 2007 | 392 | 2007 |
| Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma SF Barrington, W Qian, EJ Somer, A Franceschetto, B Bagni, E Brun, ... European journal of nuclear medicine and molecular imaging 37, 1824-1833, 2010 | 382 | 2010 |
| The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease A Gallamini, L Rigacci, F Merli, L Nassi, A Bosi, I Capodanno, S Luminari, ... haematologica 91 (4), 475-481, 2006 | 368 | 2006 |
| ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma M Dreyling, C Thieblemont, A Gallamini, L Arcaini, E Campo, O Hermine, ... Annals of Oncology 24 (4), 857-877, 2013 | 355 | 2013 |
| International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers A Biggi, A Gallamini, S Chauvie, M Hutchings, L Kostakoglu, M Gregianin, ... Journal of Nuclear Medicine 54 (5), 683-690, 2013 | 336 | 2013 |
| Positron emission tomography (PET) in oncology A Gallamini, C Zwarthoed, A Borra Cancers 6 (4), 1821-1889, 2014 | 326 | 2014 |
| Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA Working Party A Bacigalupo, G Broccia, G Corda, W Arcese, M Carotenuto, A Gallamini, ... | 302 | 1995 |
| Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis … M Ladetto, F De Marco, F Benedetti, U Vitolo, C Patti, A Rambaldi, ... Blood, The Journal of the American Society of Hematology 111 (8), 4004-4013, 2008 | 293 | 2008 |
| The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale A Gallamini, SF Barrington, A Biggi, S Chauvie, L Kostakoglu, ... Haematologica 99 (6), 1107, 2014 | 289 | 2014 |
| An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax E Itti, M Meignan, A Berriolo-Riedinger, A Biggi, AF Cashen, P Véra, ... European journal of nuclear medicine and molecular imaging 40, 1312-1320, 2013 | 269 | 2013 |
| ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) M Ghielmini, U Vitolo, E Kimby, S Montoto, J Walewski, M Pfreundschuh, ... Annals of oncology 24 (3), 561-576, 2013 | 248 | 2013 |
| Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma M Sasanelli, M Meignan, C Haioun, A Berriolo-Riedinger, ... European journal of nuclear medicine and molecular imaging 41, 2017-2022, 2014 | 223 | 2014 |
| Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B G Todeschini, S Secchi, E Morra, U Vitolo, E Orlandi, F Pasini, E Gallo, ... British journal of cancer 90 (2), 372-376, 2004 | 222 | 2004 |
